In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Adaptimmune Therapeutics Plc ADR’s stock clocked out at $0.46, up 1.42% from its previous closing price of $0.45. In other words, the price has increased by $1.42 from its previous closing price. On the day, 1.36 million shares were traded. ADAP stock price reached its highest trading level at $0.4715 during the session, while it also had its lowest trading level at $0.4468.
Ratios:
To gain a deeper understanding of ADAP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.82 and its Current Ratio is at 3.85. In the meantime, Its Debt-to-Equity ratio is 0.93 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 30, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On May 30, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $3.15.
On March 24, 2023, Bryan Garnier started tracking the stock assigning a Buy rating and target price of $3.60.Bryan Garnier initiated its Buy rating on March 24, 2023, with a $3.60 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 17 ’25 when Norry Elliot sold 5,584 shares for $0.58 per share. The transaction valued at 3,243 led to the insider holds 7,510 shares of the business.
Lunger John sold 5,584 shares of ADAP for $3,243 on Jan 17 ’25. The Chief Patient Supply Officer now owns 7,510 shares after completing the transaction at $0.58 per share. On Jan 17 ’25, another insider, Bertrand William C JR, who serves as the Chief Operating Officer of the company, sold 5,584 shares for $0.58 each. As a result, the insider received 3,243 and left with 7,510 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 116861768 and an Enterprise Value of 589576192. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.67 while its Price-to-Book (P/B) ratio in mrq is 1.46. Its current Enterprise Value per Revenue stands at 3.368 whereas that against EBITDA is -22.257.
Stock Price History:
The Beta on a monthly basis for ADAP is 2.60, which has changed by -0.6758865 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, ADAP has reached a high of $1.65, while it has fallen to a 52-week low of $0.44. The 50-Day Moving Average of the stock is -19.07%, while the 200-Day Moving Average is calculated to be -45.98%.
Shares Statistics:
It appears that ADAP traded 1.48M shares on average per day over the past three months and 1294590 shares per day over the past ten days. A total of 255.70M shares are outstanding, with a floating share count of 226.47M. Insiders hold about 11.49% of the company’s shares, while institutions hold 37.31% stake in the company. Shares short for ADAP as of 1740700800 were 6358415 with a Short Ratio of 4.30, compared to 1738281600 on 6878898. Therefore, it implies a Short% of Shares Outstanding of 6358415 and a Short% of Float of 3.73.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
